| 1 | Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study. (Sangha KS, Jakubecz C, Maynard M, Hernandez RS, Esmaeili S, Zabeti A, Abboud H, Serra A, Woodson S, Obeidat AZ) Mult Scler 2026 Mar;32(3):338-346 |
| 7 | TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. (Runaas L, Fank S, Palen K, Szabo A, Rein L, Ying G, Salzman N, Samanas L, Abedin SM, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters NR, Peled JU, Johnson B, Kearl T, Drobyski WR) Blood Adv 2026 Feb 03 |
| 1 | Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. (Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, Barve M, Tarhini AA, Bockorny B, Sonpavde G, Park D, Babu S, Ju Y, Liu L, Henry S, Tirucherai GS, DeWall S, Qatanani M, Marantz JL, Gan L) Nat Med 2026 Mar;32(3):992-1001 |
| 1 | Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. (Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS) Urol Oncol 2026 Jan;44(1):65.e1-65.e11 |
| 1 | Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer. (Kim H, Deng W, Zamarin D, Xiao Y, Chino J, Benedict S, Nguyen H, Lowenstein J, McNulty S, Ghamande S, Ferguson C, Mell L, Holman LL, Mathews C, Quick A, Olawaiye A, Hopp E, Mannel R, Leath III CA, O'Cearbhaill RE, Aghajanian C, Schilder RJ, Mayadev J) Brachytherapy 2026;25(1):127-135 1 Citation |
| 1 | Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children. (Longnecker A, Foschi CM, Carlberg VM, Swanson L, Holland KE) Pediatr Dermatol 2026;43(2):382-386 1 Citation |
| 2 | Evaluating Outcomes of Live-Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis. (Bruess GES, Barry KK, Olsen GM, Foschi CM, Cook E, Liegl M, Pan AY, Lalor L) Pediatr Dermatol 2026;43(2):330-332 1 Citation |
| 1 | Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study. (Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor Á, Townsend W, André M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C) Blood Adv 2025 Dec 09;9(23):6205-6217 4 Citations |
| 1 | Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. (Blauvelt A, Langley RG, Lebwohl M, Strober B, Warren RB, Puig L, Morita A, Gordon KB, Fernandez-Peñas P, Kavanagh S, López Pinto JM, Lambert J, Hoepken B, Deherder D, Cross N, Thaçi D) J Am Acad Dermatol 2025 Sep;93(3):644-653 10 Citations |
| 1 | Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study. (Gordon KB, Augustin M, Barker J, Tada Y, Lebwohl MG, Tang M, Hofmann P, Thoma C, Gottlieb AB) J Am Acad Dermatol 2025 Jun;92(6):1235-1242 3 Citations |
| 1 | Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. (Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C) Nat Med 2025 May;31(5):1539-1546 34 Citations |
| 4 | Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia. (Abedin SM, Guru Murthy GS, Hamadani M, Michaelis LC, Carlson KS, Runaas L, Gauger K, Desai AG, Chen MM, Li KL, Rotibi M, Syed U, Vusirikala M, Harrington A, Atallah EL) Leukemia 2025 Apr;39(4):837-843 8 Citations |
| 1 | Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders. (Saran A, Nishizaki D, Lippman SM, Kato S, Kurzrock R) Cytokine Growth Factor Rev 2025 Jun;83:35-44 26 Citations |
| 1 | Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report. (Abboud H, Subei A, Sengul B, Shin RK, Goulette P, Walch R, Coté J, Pace R, Obeidat AZ, Ferayorni L, Gholizadeh S) Front Immunol 2024;15:1526563 3 Citations |
| 2 | The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma. (Ahmed G, Hamadani M, Al-Juhaishi T) Expert Opin Biol Ther 2025;25(2):161-173 2 Citations |
| 1 | Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab. (Gurski CJ, Hajiyeva Z, Veltri AJ, Fenton K, O'Dell S, Obeidat AZ, Dittel BN) J Neuroimmunol 2025 Feb 15;399:578502 4 Citations |
| 2 | Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. (Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC) Haematologica 2025 Mar 01;110(3):706-714 7 Citations |
| 1 | Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study. (Hamadani M, Caimi PF, Hess B, Radford J, Solh M, Zinzani PL, Wang L, Xu ZC, Carlo-Stella C) Future Oncol 2025 Feb;21(3):261-270 |
| 1 | Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary. (Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, Knab T, Zammarchi F, Cucchi D, Pantano S, Havenith K, Boni J) Future Oncol 2025 Feb;21(3):271-279 1 Citation |
| 1 | Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, Elijah J, George A, Attwood K, Shaikh SS, Chaudhary LN, Abdou Y, Gandhi S) JCO Oncol Pract 2025 May;21(5):620-628 21 Citations |
| 1 | Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. (Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL, AGAVE-201 Investigators) N Engl J Med 2024 Sep 19;391(11):1002-1014 104 Citations |
| 1 | Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience. (Krishnan J, Patel A, Roy AM, Alharbi M, Kapoor A, Yao S, Khoury T, Hong CC, Held N, Chakraborty A, Kaliniski P, Salman A, Catalfamo K, Attwood K, Kirtani V, Shaikh SS, Chaudhary LN, Gandhi S) Clin Breast Cancer 2024 Dec;24(8):e701-e711.e2 11 Citations |
| 1 | Aduhelm (aducanumab-avwa) Controversy. (Busse K, El-Alfy AT) WMJ 2024;123:P2 |
| 1 | Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. (Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES) Prostate Cancer Prostatic Dis 2025 Jun;28(2):411-418 13 Citations |
| 1 | Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis. (Tarvin SE, Sherman MA, Kim H, Balmuri N, Brown AG, Chow A, Gewanter HL, de Guzman MM, Huber AM, Kim S, Klein-Gitelman MS, Perron MM, Robinson AB, Sabbagh SE, Savani S, Shenoi S, Spitznagle J, Stingl C, Syverson G, Tory H, Spencer C, Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup) Arthritis Care Res (Hoboken) 2024 Nov;76(11):1532-1539 6 Citations |
| 5 | Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M) Blood Adv 2024 Aug 27;8(16):4320-4329 15 Citations |
| 1 | Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement. (Becker R, Rigsby M, Suchi M, Lerner DG, Chugh A) J Pediatr Gastroenterol Nutr 2024 Jun;78(6):1337-1341 4 Citations |
| 1 | Bimekizumab for the treatment of psoriasis. (Thapar M, Patel M, Gordon K) Immunotherapy 2024 Apr;16(7):431-446 |
| 5 | Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response. (Bobholz SA, Hoefs A, Hamburger J, Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D, Krucoff M, Banerjee A, LaViolette PS) J Neurooncol 2024 Apr;167(2):233-241 8 Citations |
| 1 | Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. (Mutch D, Voulgari A, Chen XM, Bradley WH, Oaknin A, Perez Fidalgo JA, Montosa FG, Herraez AC, Holloway RW, Powell MA, Nowicka M, Schaefer G, Merchant M, Yan Y) Cancer 2024 Jun 01;130(11):1940-1951 5 Citations |
| 1 | Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. (Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, de Cuyper D, Davies O, Thaçi D) Br J Dermatol 2024 Mar 15;190(4):477-485 31 Citations |
| 1 | Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. (Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL) Blood Adv 2024 Jan 09;8(1):93-98 7 Citations |
| 1 | MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. (Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F) J Clin Oncol 2024 Jan 20;42(3):258-265 45 Citations |
| 1 | The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. (Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD) Cancer Res Commun 2023 Oct 11;3(10):2074-2081 1 Citation |
| 1 | Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. (Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C) Haematologica 2024 Apr 01;109(4):1184-1193 64 Citations |
| 1 | Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. (Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM) Hematol Oncol 2023 Dec;41(5):848-857 |
| 2 | Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic. (Yee MD, McCarthy J, Quinn B, Surani A) WMJ 2023 May;122(2):134-137 5 Citations |
| 1 | LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. (Adashek JJ, Kato S, Nishizaki D, Miyashita H, De P, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Lippman S, Kurzrock R) Cancer Med 2023 Jun;12(12):13155-13166 22 Citations |
| 1 | Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy. (Kozak M, Rubenstein W, Okwan-Duodu D, Friedman K, Nassir Y, Perez-Alvarez I, Gibb DR, Klapper E, Pepkowitz S) Transfusion 2023 Jun;63(6):1241-1245 3 Citations |
| 1 | Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. (Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A) Br J Cancer 2023 Jun;128(12):2227-2235 29 Citations |
| 2 | Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. (Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LM, Andolina JR, Shenoy S, Roehrs P, Hanna R, Talano JA, Schultz KR, Stenger EO, Lin H, Zoref-Lorenz A, McClain KL, Jordan MB, Man TK, Allen CE, Marsh RA) Blood Adv 2023 Jul 25;7(14):3725-3734 4 Citations |
| 1 | Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. (Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C) N Engl J Med 2023 Jun 08;388(23):2159-2170 |
| 1 | Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. (Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL) Leuk Lymphoma 2023 Jan;64(1):130-139 21 Citations |
| 1 | Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. (Colman RJ, Mizuno T, Fukushima K, Haslam DB, Hyams JS, Boyle B, Noe JD, D'Haens GR, Van Limbergen J, Chun K, Yang J, Denson LA, Ollberding NJ, Vinks AA, Minar P) Aliment Pharmacol Ther 2023 Mar;57(5):524-539 23 Citations |
| 2 | Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. (Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M) JAMA Netw Open 2022 Oct 03;5(10):e2238961 35 Citations |
| 1 | Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab. (Yarur AJ, McGovern D, Abreu MT, Cheifetz A, Papamichail K, Deepak P, Bruss A, Beniwal-Patel P, Dubinsky M, Targan SR, Melmed GY) Clin Gastroenterol Hepatol 2023 Oct;21(11):2908-2917.e10 30 Citations |
| 6 | Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256 10 Citations |
| 4 | Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. (Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C) Am J Hematol 2022 Dec;97(12):E451-E453 13 Citations |
| 1 | Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. (Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME, ICPi-AKI Consortium) Kidney Int 2022 Oct;102(4):930-935 9 Citations |
| 1 | Nivolumab-associated Nasal Polyposis and Eosinophilic Asthma Responsive to Benralizumab, An Anti-IL5R Biologic. (Rembalski S, Steinberg JA) J Immunother 2022 Oct 01;45(8):370-373 7 Citations |
| 1 | Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. (Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF) Blood Adv 2022 Aug 23;6(16):4736-4739 5 Citations |
| 1 | Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab. (Fuja C, Kothary V, Carll TC, Singh S, Mansfield P, Wool GD) Transfusion 2022 Jul;62(7):1446-1451 14 Citations |
| 1 | The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. (Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C) Blood 2022 Jul 28;140(4):303-308 43 Citations |
| 1 | Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. (Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C) Clin Lymphoma Myeloma Leuk 2022 Aug;22(8):e738-e744 7 Citations |
| 1 | Pregnancy associated TMA in 13-year-old patient successfully treated with Eculizumab: case report. (Cody E, Claes D, Taylor V, Erkan E) BMC Nephrol 2022 Apr 15;23(1):147 1 Citation |
| 1 | Aducanumab. (Busse K, El-Alfy AT) WMJ 2022;121:P1 |
| 1 | A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. (Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R) Cancer Med 2022 Jul;11(14):2790-2800 22 Citations |
| 1 | Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. (Torka P, Akhtar OS, Reddy NM, Baysal BE, Kader A, Groman A, Nichols J, Mavis C, Tario JD, Block AW, Sait SNJ, Ghione P, Sundaram S, Przespolewski ER, Mohr A, Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ) Cancer 2022 Apr 15;128(8):1595-1604 2 Citations |
| 1 | Where do we go after GiACTA? (Putman M, Sattui S, Conway R) Rheumatology (Oxford) 2022 Jul 06;61(7):2720-2721 |
| 1 | Loncastuximab tesirine for diffuse large B-cell lymphoma. (Zurko J, Hamadani M) Drugs Today (Barc) 2021 Dec;57(12):733-743 2 Citations |
| 1 | Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. (Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C) Cancer Discov 2022 Mar 01;12(3):654-669 78 Citations |
| 1 | Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. (Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ) Ophthalmology 2022 Apr;129(4):438-449 141 Citations |
| 1 | Continued Basal Zone Expansion After Resolution of Eosinophilia in a Child With Eosinophilic Esophagitis on Benralizumab. (Wenzel AA, Wadhwani N, Wechsler JB) J Pediatr Gastroenterol Nutr 2022 Feb 01;74(2):e31-e34 12 Citations |
| 1 | Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. (Ahmed N, Hamadani M) Expert Rev Anticancer Ther 2021 Dec;21(12):1313-1320 6 Citations |
| 1 | Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). (EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)) Lancet 2021 Nov 06;398(10312):1713-1725 267 Citations |
| 1 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H) Lancet Oncol 2021 Sep;22(9):1290-1300 372 Citations |
| 1 | Term Pregnancy After Complete Response of Placental Site Trophoblastic Tumor to Immunotherapy. (Polnaszek B, Mullen M, Bligard K, Raghuraman N, Massad LS) Obstet Gynecol 2021 Jul 01;138(1):115-118 23 Citations |
| 1 | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, George S, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ) JAMA Oncol 2021 Aug 01;7(8):1225-1230 187 Citations |
| 2 | Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. (Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A) Leuk Res 2021 Oct;109:106648 |
| 1 | Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. (Narla S, Silverberg JI, Simpson EL) J Am Acad Dermatol 2022 Mar;86(3):628-636 78 Citations |
| 1 | Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. (Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM) Br J Dermatol 2021 Dec;185(6):1146-1159 79 Citations |
| 1 | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. (Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG) Leukemia 2021 Dec;35(12):3526-3533 19 Citations |
| 1 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C) Lancet Oncol 2021 Jun;22(6):790-800 386 Citations |
| 1 | Burosumab treatment for fibrous dysplasia. (Gladding A, Szymczuk V, Auble BA, Boyce AM) Bone 2021 Sep;150:116004 35 Citations |
| 1 | Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. (Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators) Lancet Oncol 2021 May;22(5):609-619 374 Citations |
| 1 | Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. (Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, Gatopoulou A, Karatzas P, Kopylov U, Michalopoulos G, Michopoulos S, Navaneethan U, Rubin DT, Siffledeen J, Singh A, Soufleris K, Stein D, Demuth D, Mantzaris GJ) J Crohns Colitis 2021 Oct 07;15(10):1694-1706 136 Citations |
| 1 | A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (Ribrag V, Lee ST, Rizzieri D, Dyer MJS, Fayad L, Kurzrock R, Andritsos L, Bouabdallah R, Hayat A, Bacon L, Jiang Y, Miah K, Delafont B, Hamid O, Anyanwu S, Martinez P, Hess B) Clin Lymphoma Myeloma Leuk 2021 May;21(5):309-317.e3 27 Citations |
| 1 | Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. (Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M) Lancet 2021 Feb 06;397(10273):487-498 268 Citations |
| 1 | Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. (Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A) Lancet 2021 Feb 06;397(10273):475-486 251 Citations |
| 4 | The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. (Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR) Transl Psychiatry 2021 Jan 18;11(1):58 60 Citations |
| 1 | Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators. (Douglas RS, Wang Y, Dailey RA, Harris GJ, Wester ST, Schiffman JS, Tang RA, Fowler B, Fleming J, Smith TJ) J Neuroophthalmol 2021 Dec 01;41(4):461-468 33 Citations |
| 1 | Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. (Williams C, Stewart E, Conzen KD, Wolf S, Tran TT) Semin Cardiothorac Vasc Anesth 2021 Sep;25(3):200-207 6 Citations |
| 1 | Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. (Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS) Blood 2021 May 13;137(19):2634-2645 156 Citations |
| 1 | Predictors and outcomes of healthcare-associated infections in COVID-19 patients. (Kumar G, Adams A, Hererra M, Rojas ER, Singh V, Sakhuja A, Meersman M, Dalton D, Kethireddy S, Nanchal R, Guddati AK) Int J Infect Dis 2021 Mar;104:287-292 71 Citations |
| 1 | Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. (DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK) Clin Cancer Res 2021 Feb 01;27(3):759-774 70 Citations |
| 1 | Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. (Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Bansal A, Srivastava A, Zhou Y, Finkel D, Green A, Mallappallil M, Faugno AJ, Zhang J, Velez JCQ, Shaefi S, Parikh CR, Charytan DM, Athavale AM, Friedman AN, Redfern RE, Short SAP, Correa S, Pokharel KK, Admon AJ, Donnelly JP, Gershengorn HB, Douin DJ, Semler MW, Hernán MA, Leaf DE, STOP-COVID Investigators) JAMA Intern Med 2021 Jan 01;181(1):41-51 410 Citations |
| 1 | Eculizumab treatment for renal failure in a pediatric patient with COVID-19. (Mahajan R, Lipton M, Broglie L, Jain NG, Uy NS) J Nephrol 2020 Dec;33(6):1373-1376 36 Citations |
| 1 | Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. (Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Récher C, Stiff PJ, Pettit KM, Löwenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF) Blood 2021 Feb 11;137(6):751-762 288 Citations |
| 1 | Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. (Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB) Am J Clin Dermatol 2020 Dec;21(6):881-890 31 Citations |
| 1 | The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. (Subbiah V, Solit DB, Chan TA, Kurzrock R) Ann Oncol 2020 Sep;31(9):1115-1118 202 Citations |
| 1 | Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric Primary Sclerosing Cholangitis Consortium. (Laborda TJ, Ricciuto A, Aumar M, Carman N, DiGuglielmo M, Draijer LG, Furuya KN, Gupta N, Koot BGP, Loomes KM, Lytvyak E, Martinez M, Miloh T, Montano-Loza AJ, Perito ER, Sathya P, Shah U, Shteyer E, Singh R, Taylor A, Valentino PL, Vitola B, Zerofsky M, Zizzo A, Deneau MR) J Pediatr Gastroenterol Nutr 2020 Oct;71(4):459-464 19 Citations |
| 1 | Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. (Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A, COVID-19 Global Rheumatology Alliance) Arthritis Rheumatol 2021 Jan;73(1):36-47 50 Citations |
| 1 | A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. (Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM) Blood 2020 Nov 19;136(21):2401-2409 137 Citations |
| 3 | Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? (Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MC) Blood 2020 Jul 02;136(1):137-139 60 Citations |
| 1 | A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. (Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T) Leukemia 2020 Dec;34(12):3298-3309 46 Citations |
| 1 | Anifrolumab in Systemic Lupus Erythematosus. (Putman M) N Engl J Med 2020 Apr 23;382(17):1665-1666 |
| 1 | Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient. (Wenzel AA, Strople J, Melin-Aldana H, Brown JB) J Pediatr Gastroenterol Nutr 2020 Jul;71(1):e47-e48 7 Citations |
| 1 | Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. (Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ) Blood Adv 2020 Feb 11;4(3):449-457 54 Citations |
| 1 | Teprotumumab for the Treatment of Active Thyroid Eye Disease. (Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ) N Engl J Med 2020 Jan 23;382(4):341-352 621 Citations |
| 1 | A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. (Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group) Br J Dermatol 2020 Jun;182(6):1348-1358 138 Citations |
| 1 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD) Lancet Oncol 2020 Feb;21(2):207-221 697 Citations |
| 1 | Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. (Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM) Blood Adv 2019 Dec 10;3(23):4136-4146 44 Citations |
| 1 | Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. (Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A) J Am Acad Dermatol 2020 Apr;82(4):936-945 84 Citations |
| 1 | A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. (Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA) Clin Cancer Res 2019 Dec 01;25(23):6986-6994 99 Citations |
| 1 | Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. (Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M) Qual Life Res 2020 Feb;29(2):369-380 5 Citations |
| 1 | Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. (Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB) J Dermatol 2019 Dec;46(12):1141-1152 15 Citations |
| 1 | Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. (Weyand AC, Flood VH, Shavit JA, Pipe SW) Blood Adv 2019 Sep 24;3(18):2748-2750 45 Citations |
| 1 | Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. (Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C) J Eur Acad Dermatol Venereol 2020 Feb;34(2):301-309 30 Citations |
| 1 | In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. (Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T) Leukemia 2020 Jan;34(1):317-321 31 Citations |
| 1 | Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. (Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K) J Dermatolog Treat 2020 Dec;31(8):763-768 13 Citations |
| 1 | Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. (Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K) J Invest Dermatol 2019 Dec;139(12):2437-2446.e1 94 Citations |
| 1 | Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors. (Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ) Am J Kidney Dis 2019 Dec;74(6):853-856 72 Citations |
| 2 | Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. (Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC) J Crohns Colitis 2019 Aug 14;13(8):963-969 65 Citations |
| 5 | A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 Aug;25(8):1492-1497 25 Citations |
| 1 | Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. (Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ) Leukemia 2019 Sep;33(9):2266-2275 542 Citations |
| 1 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. (Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J) Lancet Oncol 2019 Apr;20(4):518-530 505 Citations |
| 1 | Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. (Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, Berens B, Patel A, Ungaro R, Bahur B, Dubinsky M, Stein DJ) Dig Dis Sci 2019 Jun;64(6):1651-1659 43 Citations |
| 1 | Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. (Gregory M, Weaver KN, Hoversten P, Hicks SB, Patel D, Ciorba MA, Gutierrez AM, Beniwal-Patel P, Palam S, Syal G, Herfarth HH, Christophi G, Raffals L, Barnes EL, Deepak P) Inflamm Bowel Dis 2019 Aug 20;25(9):1569-1576 71 Citations |
| 1 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2019 Apr;80(4):1029-1072 849 Citations |
| 1 | Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. (Yucebay F, Matthews C, Puto M, Li J, William B, Jaglowski SM, Penza SL, Vasu S, Benson DM, Andritsos LA, Devine SM, Efebera YA, Roddy JVF) Leuk Lymphoma 2019 Sep;60(9):2223-2229 21 Citations |
| 1 | A Case of Pansclerotic Morphea Treated With Tocilizumab. (Zhang A, Nocton J, Chiu Y) JAMA Dermatol 2019 Mar 01;155(3):388-389 30 Citations |
| 1 | Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. (Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB) Biol Blood Marrow Transplant 2019 Apr;25(4):720-727 60 Citations |
| 1 | Hemolytic Uremic Syndrome. (Cody EM, Dixon BP) Pediatr Clin North Am 2019 Feb;66(1):235-246 102 Citations |
| 1 | Obstructive nephropathy: simple yet complicated! (Koratala A, Morales Lappot J) Intern Emerg Med 2019 Mar;14(2):315-317 2 Citations |
| 1 | IL-23 inhibitors for moderate-to-severe psoriasis. (Ibler E, Gordon KB) Semin Cutan Med Surg 2018 Sep;37(3):158-162 13 Citations |
| 1 | Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. (Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R) Cancer Immunol Res 2018 Oct;6(10):1129-1135 98 Citations |
| 1 | International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC) Blood 2018 Nov 15;132(20):2115-2124 349 Citations |
| 1 | Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. (Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL) Bone Marrow Transplant 2019 Feb;54(2):212-217 44 Citations |
| 1 | Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. (Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A) JAMA Dermatol 2018 Jun 01;154(6):676-683 112 Citations |
| 1 | Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. (Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K) J Eur Acad Dermatol Venereol 2018 Nov;32(11):1940-1949 82 Citations |
| 1 | Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. (Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G) J Am Acad Dermatol 2018 Aug;79(2):294-301.e6 26 Citations |
| 1 | Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. (Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R) J Eur Acad Dermatol Venereol 2018 Aug;32(8):1305-1313 36 Citations |
| 1 | Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. (Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ) Br J Dermatol 2018 Aug;179(2):320-328 69 Citations |
| 11 | Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 Apr;103(4):717-727 44 Citations |
| 1 | Indications and Methods of Anticoagulation Reversal. (Holzmacher JL, Sarani B) Surg Clin North Am 2017 Dec;97(6):1291-1305 11 Citations |
| 1 | Multicentric Reticulohistiocytosis: A Multicenter Case Series and Review of Literature. (Kumar B, Singh N, Rahnama-Moghadam S, Wanat KA, Ijdo JW, Werth VP) J Clin Rheumatol 2018 Jan;24(1):45-49 16 Citations |
| 1 | Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. (Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B) Value Health 2017 Sep;20(8):1174-1179 11 Citations |
| 1 | Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM) Br J Dermatol 2018 Jan;178(1):132-139 75 Citations |
| 2 | Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. (Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB) Transfusion 2017 Nov;57(11):2775-2781 28 Citations |
| 1 | Pembrolizumab for Recurrent Conjunctival Melanoma. (Kini A, Fu R, Compton C, Miller DM, Ramasubramanian A) JAMA Ophthalmol 2017 Aug 01;135(8):891-892 61 Citations |
| 1 | Elotuzumab as a novel anti-myeloma immunotherapy. (Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D) Hum Vaccin Immunother 2017 Aug 03;13(8):1751-1757 6 Citations |
| 1 | Comparative Evaluation of αCD40 (2C10R4) and αCD154 (5C8H1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model. (OʼNeill NA, Zhang T, Braileanu G, Sun W, Cheng X, Hershfeld A, Laird CT, Kronfli A, Hock LA, Dahi S, Kubicki N, Sievert E, Hassanein W, Cimeno A, Pierson RN 3rd, Azimzadeh AM) Transplantation 2017 Sep;101(9):2038-2047 17 Citations |
| 2 | PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 219 Citations |
| 1 | Teprotumumab for Thyroid-Associated Ophthalmopathy. (Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS) N Engl J Med 2017 May 04;376(18):1748-1761 650 Citations |
| 1 | BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC) J Clin Oncol 2017 May 01;35(13):1437-1443 437 Citations |
| 1 | Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. (Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R) Clin Cancer Res 2017 Aug 01;23(15):4242-4250 765 Citations |
| 1 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. (Moy JD, Moskovitz JM, Ferris RL) Eur J Cancer 2017 May;76:152-166 90 Citations |
| 1 | Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. (Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB) J Eur Acad Dermatol Venereol 2017 Jun;31(6):1004-1013 66 Citations |
| 1 | NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. (Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, Mashal R, Nathan DG) PLoS One 2017;12(2):e0171067 29 Citations |
| 1 | An Investigation of Extracellular Histones in Pig-To-Baboon Organ Xenotransplantation. (Li T, Lee W, Hara H, Long C, Ezzelarab M, Ayares D, Huang H, Wang Y, Esmon CT, Cooper DKC, Iwase H) Transplantation 2017 Oct;101(10):2330-2339 38 Citations |
| 1 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. (Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB) J Am Acad Dermatol 2017 Mar;76(3):418-431 678 Citations |
| 1 | CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. (Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C) Biol Blood Marrow Transplant 2017 Mar;23(3):405-411 18 Citations |
| 1 | Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. (Kurzrock R, Stewart DJ) Clin Cancer Res 2017 Mar 01;23(5):1137-1148 43 Citations |
| 1 | PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. (Goodman A, Patel SP, Kurzrock R) Nat Rev Clin Oncol 2017 Apr;14(4):203-220 409 Citations |
| 1 | Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group) N Engl J Med 2016 Jul 28;375(4):345-56 752 Citations |
| 1 | Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. (Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S) Bone Marrow Transplant 2016 Sep;51(9):1241-4 60 Citations |
| 1 | Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. (Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB) JAMA Dermatol 2016 Jun 01;152(6):661-9 53 Citations |
| 1 | Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. (Devata S, Wilcox RA) Am J Clin Dermatol 2016 Jun;17(3):225-37 30 Citations |
| 1 | A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. (Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H) Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):139-45 64 Citations |
| 3 | Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. (Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ, Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup-Poulsen T, AIDA Study Group, Hessner MJ) Eur J Immunol 2016 Apr;46(4):1030-46 52 Citations |
| 1 | Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease? (Field JJ) Hematology Am Soc Hematol Educ Program 2015;2015:426-32 5 Citations |
| 1 | Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. (Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ) BMC Cancer 2015 Oct 16;15:713 46 Citations |
| 1 | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. (Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A) N Engl J Med 2015 Oct;373(14):1318-28 765 Citations |
| 1 | Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience. (Yelken B, Arpalı E, Görcin S, Kocak B, Karatas C, Demiralp E, Turkmen A) Transplant Proc 2015;47(6):1754-9 34 Citations |
| 1 | A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. (Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K) N Engl J Med 2015 Jul 09;373(2):136-44 284 Citations |
| 1 | Tocilizumab for steroid refractory acute graft-versus-host disease. (Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA) Leuk Lymphoma 2016;57(1):81-5 40 Citations |
| 1 | Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC) Blood 2015 Aug 13;126(7):842-50 122 Citations |
| 1 | The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. (Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A) Oncologist 2015 Jul;20(7):737-41 15 Citations |
| 1 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. (Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr) N Engl J Med 2015 Jun 25;372(26):2509-20 8339 Citations |
| 1 | Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. (Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Invest New Drugs 2015 Jun;33(3):621-31 61 Citations |
| 1 | A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. (Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL) J Eur Acad Dermatol Venereol 2016 May;30(5):864-5 29 Citations |
| 1 | Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. (Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators) JAMA Ophthalmol 2015 May;133(5):589-97 75 Citations |
| 1 | Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW) N Engl J Med 2015 Mar 26;372(13):1193-203 1441 Citations |
| 1 | A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. (Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS) Oncotarget 2014 Nov 30;5(22):11154-67 12 Citations |
| 1 | miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC) Leukemia 2015 May;29(5):1210-3 20 Citations |
| 1 | Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. (Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R) Oncotarget 2014 Nov 15;5(21):10280-92 57 Citations |
| 1 | Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. (Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R) Invest New Drugs 2015 Feb;33(1):215-24 10 Citations |
| 1 | Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. (Shaw BE, Lee F, Krishnamurthy S, Byrne JL, Seedhouse C, Mayor NP, Maldonado-Torres H, Saudemont A, Marsh SG, Madrigal JA, Russell NH) Bone Marrow Transplant 2015 Feb;50(2):237-43 2 Citations |
| 1 | A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. (Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R) Invest New Drugs 2015 Feb;33(1):177-86 20 Citations |
| 1 | The role of integrin antagonists in the treatment of inflammatory bowel disease. (Beniwal-Patel P, Saha S) Expert Opin Biol Ther 2014 Dec;14(12):1815-23 5 Citations |
| 1 | Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study. (Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C) Bone Marrow Transplant 2015 Jan;50(1):82-6 9 Citations |
| 1 | A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. (Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M) J Am Acad Dermatol 2014 Dec;71(6):1176-82 98 Citations |
| 1 | Autoimmune hemolytic anemia and thrombocytopenia attributed to an intrauterine contraceptive device. (Khawandanah MO, Weiss SM, Cherry MA, Maymani H, Selby GB, Aster RH, George JN, Holter Chakrabarty JL) Transfusion 2015 Mar;55(3):657-60 2 Citations |
| 1 | The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface. (Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A) PLoS One 2014;9(7):e103254 9 Citations |
| 1 | New and emerging therapies in psoriasis. (Leonardi CL, Gordon KB) Semin Cutan Med Surg 2014 Mar;33(2 Suppl 2):S37-41 22 Citations |
| 1 | Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. (Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM) Oncotarget 2014 Oct 15;5(19):9049-64 23 Citations |
| 1 | Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. (Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R) Cancer 2014 Jul 15;120(14):2164-73 29 Citations |
| 1 | Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. (Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R) Oncotarget 2014 Apr 15;5(7):1846-55 34 Citations |
| 1 | Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. (Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R) Anticancer Res 2014 Apr;34(4):1939-45 27 Citations |
| 1 | Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. (Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A) Oncologist 2014 Apr;19(4):426-8 11 Citations |
| 1 | HER2 aberrations in cancer: implications for therapy. (Yan M, Parker BA, Schwab R, Kurzrock R) Cancer Treat Rev 2014 Jul;40(6):770-80 202 Citations |
| 1 | Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. (Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR) J Natl Compr Canc Netw 2014 Feb;12(2):194-203 3 Citations |
| 1 | Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. (Pilch NA, Taber DJ, Moussa O, Thomas B, Denmark S, Meadows HB, McGillicuddy JW, Srinivas TR, Baliga PK, Chavin KD) Ann Surg 2014 May;259(5):888-93 40 Citations |
| 2 | Irinotecan-induced immune thrombocytopenia. (Mirtsching BC, George JN, Aster RH, Curtis BR) Am J Med Sci 2014 Feb;347(2):167-9 7 Citations |
| 1 | Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. (Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R) Cancer Chemother Pharmacol 2014 Mar;73(3):495-501 54 Citations |
| 2 | Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. (Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG) Neuro Oncol 2014 Jun;16(6):880-8 112 Citations |
| 1 | Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. (Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R) Cancer Chemother Pharmacol 2014 Mar;73(3):467-73 36 Citations |
| 1 | Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. (Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R) Ann Oncol 2013 Dec;24(12):3004-11 33 Citations |
| 1 | Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. (Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG) Br J Dermatol 2014 Mar;170(3):705-15 45 Citations |
| 1 | Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A) Br J Haematol 2013 Nov;163(3):315-25 34 Citations |
| 1 | Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. (Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J, Shrom D, Wang P, Banerjee S, Gordon KB) Br J Dermatol 2013 Dec;169(6):1337-41 41 Citations |
| 1 | Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. (Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R) Mol Cancer Ther 2013 Oct;12(10):2167-75 34 Citations |
| 1 | Rationale and early clinical data on IL-17 blockade in psoriasis. (Nwe SM, Champlain AH, Gordon KB) Expert Rev Clin Immunol 2013 Jul;9(7):677-82 14 Citations |
| 1 | Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye. (Karth PA, Chang A, Wirostko W) Graefes Arch Clin Exp Ophthalmol 2014 Feb;252(2):207-11 8 Citations |
| 1 | Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. (Falchook GS, Lippman SM, Bastida CC, Kurzrock R) Head Neck 2014 Mar;36(3):E25-7 49 Citations |
| 1 | Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. (Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2013 Aug;131(8):1033-40 106 Citations |
| 1 | Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. (Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Oncotarget 2013 May;4(5):772-84 19 Citations |
| 1 | Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? (Han DP) JAMA Ophthalmol 2013 Sep;131(9):1124-6 7 Citations |
| 1 | Does spironolactone ameliorate trastuzumab-induced cardiac toxicity? (Yavas G, Elsurer R, Yavas C, Elsurer C, Ata O) Med Hypotheses 2013 Aug;81(2):231-4 8 Citations |
| 1 | P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. (Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R) Oncotarget 2013 May;4(5):705-14 105 Citations |
| 1 | Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. (Kocak B, Arpali E, Demiralp E, Yelken B, Karatas C, Gorcin S, Gorgulu N, Uzunalan M, Turkmen A, Kalayoglu M) Transplant Proc 2013 Apr;45(3):1022-5 49 Citations |
| 1 | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. (Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS) Gynecol Oncol 2013 Jul;130(1):64-8 78 Citations |
| 1 | Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. (Weinberg DV, Shapiro H, Ehrlich JS) Ophthalmology 2013 Jun;120(6):1278-82 14 Citations |
| 1 | Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. (Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R) Oncotarget 2013 Jan;4(1):118-27 32 Citations |
| 2 | Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. (Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R) Br J Cancer 2013 Mar 05;108(4):826-30 117 Citations |
| 1 | Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. (Janku F, Wheler JJ, Hong DS, Kurzrock R) Target Oncol 2013 Sep;8(3):183-188 8 Citations |
| 5 | Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. (LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2013 Apr;15(4):442-50 42 Citations |
| 1 | Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. (Diabetic Retinopathy Clinical Research Network*) JAMA Ophthalmol 2013 Mar;131(3):283-93 95 Citations |
| 1 | Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. (Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group) Ophthalmology 2013 May;120(5):1046-56 486 Citations |
| 1 | Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. (Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R) J Thorac Oncol 2013 Feb;8(2):e19-20 25 Citations |
| 1 | Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. (Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, Shaw BE, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G, British Society of Blood and Marrow Transplantation) Bone Marrow Transplant 2013 Jul;48(7):982-7 10 Citations |
| 1 | Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. (Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K, PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators) Br J Dermatol 2013 Apr;168(4):844-54 378 Citations |
| 1 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. (Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators) J Eur Acad Dermatol Venereol 2013 Dec;27(12):1535-45 199 Citations |
| 1 | Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. (Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B) J Eur Acad Dermatol Venereol 2013 Oct;27(10):1252-61 62 Citations |
| 1 | Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. (Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Ann Oncol 2013 Mar;24(3):838-42 21 Citations |
| 1 | PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. (Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, PSOLAR investigators and Steering Committee) J Drugs Dermatol 2012 Oct;11(10):1210-7 86 Citations |
| 1 | Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. (Wanat KA, Rosenbach M) Arch Dermatol 2012 Sep;148(9):1097-100 32 Citations |
| 1 | Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. (Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R) Clin Cancer Res 2012 Oct 15;18(20):5796-805 79 Citations |
| 1 | Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. (Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R) Hepatogastroenterology 2012 Jun;59(116):960-4 3 Citations |
| 1 | Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. (Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP) Ann Rheum Dis 2013 Apr;72(4):517-24 518 Citations |
| 1 | Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. (Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R) Clin Cancer Res 2012 May 01;18(9):2625-31 184 Citations |
| 1 | An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. (Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB, PHOENIX 1, PHOENIX 2, and ACCEPT investigators) J Drugs Dermatol 2012 Mar;11(3):300-12 78 Citations |
| 1 | Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. (Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA) Br J Dermatol 2012 Apr;166(4):861-72 130 Citations |
| 3 | Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. (Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H) Am J Clin Pathol 2012 Mar;137(3):403-11 24 Citations |
| 1 | Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. (Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, Dorosario AA, Chaney KS, Cutler CS, Leboeuf NR, Carter JB, Fisher DC, Kupper TS) Sci Transl Med 2012 Jan 18;4(117):117ra7 323 Citations |
| 1 | Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. (Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R) Nutr Cancer 2012;64(2):206-17 29 Citations |
| 2 | Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. (Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM) Magn Reson Med 2012 Oct;68(4):1266-72 6 Citations |
| 1 | Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. (Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R) J Clin Oncol 2012 Feb 10;30(5):e64-8 42 Citations |
| 1 | Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. (Munoz J, Hong D, Kurzrock R) Int J Hematol 2012 Jan;95(1):1-2 3 Citations |
| 1 | Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. (Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME) Breast Cancer Res Treat 2012 Jan;131(2):713-21 18 Citations |
| 1 | R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. (Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R) PLoS One 2011;6(10):e26060 38 Citations |
| 1 | A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. (Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM) J Invest Dermatol 2012 Feb;132(2):304-14 157 Citations |
| 1 | Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. (Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K) J Am Acad Dermatol 2012 May;66(5):742-51 134 Citations |
| 1 | Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. (Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM) Am J Otolaryngol 2012;33(3):349-51 21 Citations |
| 1 | A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. (Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R) Clin Cancer Res 2011 Nov 01;17(21):6840-6 48 Citations |
| 1 | Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A) JAMA 2011 Aug 24;306(8):864-71 277 Citations |
| 1 | Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. (Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB) Neuro Oncol 2011 Oct;13(10):1151-61 73 Citations |
| 1 | Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. (Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH) J Am Acad Dermatol 2012 Feb;66(2):241-51 170 Citations |
| 4 | Tocilizumab for the treatment of steroid refractory graft-versus-host disease. (Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1862-8 110 Citations |
| 1 | Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. (Ramasubramanian A, Shields CL) Br J Ophthalmol 2012 Mar;96(3):356-9 127 Citations |
| 2 | Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. (Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM) J Neurooncol 2011 Nov;105(2):233-9 19 Citations |
| 1 | Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. (Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R) J Clin Oncol 2011 Jul 01;29(19):e572-5 66 Citations |
| 1 | Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. (Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL) Br J Haematol 2011 Apr;153(2):244-52 19 Citations |
| 1 | Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. (Brinkerhoff BT, Poetker DM, Choong NW) N Engl J Med 2011 Feb 17;364(7):688-9 33 Citations |
| 1 | Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. (Piha-Paul SA, Hong DS, Kurzrock R) J Clin Oncol 2011 Apr 20;29(12):e333-5 13 Citations |
| 1 | Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. (Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R) Clin Colorectal Cancer 2010 Dec;9(5):311-4 10 Citations |
| 1 | Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J, ABT-874 Study Investigators) J Am Acad Dermatol 2011 Feb;64(2):263-74 27 Citations |
| 1 | Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional study. (Yavas G, Yildiz F, Guler S, Sargon MF, Yildiz D, Yolcu T, Tuncer M, Akyol FH) Ann Oncol 2011 May;22(5):1120-1126 13 Citations |
| 1 | Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. (Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT) Br J Cancer 2010 Oct 26;103(9):1331-4 8 Citations |
| 1 | Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. (Fuller CK, Charlson JA, Dankle SK, Russell TJ) J Am Acad Dermatol 2010 Oct;63(4):e83-4 37 Citations |
| 1 | Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. (Cohen PR, Escudier SM, Kurzrock R) Am J Clin Dermatol 2011 Feb 01;12(1):63-7 38 Citations |
| 1 | Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. (Kirchner VA, Suszynski TM, Radosevich DM, Humar A, Dunn TB, Hill MJ, Finger EB, Sutherland DE, Kandaswamy R) Transplant Proc 2010;42(6):2003-5 6 Citations |
| 1 | The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. (Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC) Blood 2010 Nov 11;116(19):3705-14 110 Citations |
| 1 | Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. (Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM) J Am Acad Dermatol 2010 Sep;63(3):448-56 149 Citations |
| 1 | A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. (Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R) Cancer 2010 Sep 01;116(17):4086-94 31 Citations |
| 1 | Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. (Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB) J Am Acad Dermatol 2010 Sep;63(3):457-65 206 Citations |
| 3 | Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. (Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P) Br J Haematol 2010 Aug;150(4):480-1 4 Citations |
| 1 | Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. (Gandhi M, Alwawi E, Gordon KB) Semin Cutan Med Surg 2010 Mar;29(1):48-52 58 Citations |
| 1 | Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK) Ophthalmology 2010 Jun;117(6):1064-1077.e35 1321 Citations |
| 1 | Angioedema occurring in pediatric patients with Crohn disease treated with adalimumab. (Adamiak T, Stephens M, Werlin SL) J Pediatr Gastroenterol Nutr 2010 Aug;51(2):223-5 3 Citations |
| 1 | A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. (Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L) Clin Cancer Res 2010 Apr 15;16(8):2458-65 177 Citations |
| 1 | A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. (Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D) Clin Cancer Res 2010 Feb 15;16(4):1256-63 155 Citations |
| 1 | Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? (Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM) Oncologist 2010;15(2):130-41 107 Citations |
| 2 | Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. (Gore E, Currey A, Choong N) J Thorac Oncol 2009 Dec;4(12):1590-1 23 Citations |
| 1 | Ranibizumab for coloboma-related choroidal neovascular membrane in a child. (Goodwin P, Shields CL, Ramasubramanian A, Brown GC, Shields JA) J AAPOS 2009 Dec;13(6):616-7 18 Citations |
| 1 | The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. (Krilov LR, Weiner LB, Yogev R, Fergie J, Katz BZ, Henrickson KJ, Welliver RC Sr) Pediatrics 2009 Dec;124(6):1682-4 25 Citations |
| 1 | Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. (Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL) Clin Cancer Res 2009 Dec 01;15(23):7266-76 115 Citations |
| 1 | Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. (Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS) Clin Cancer Res 2009 Oct 15;15(20):6358-66 40 Citations |
| 1 | Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. (Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS) Am J Gastroenterol 2009 Dec;104(12):3042-9 118 Citations |
| 1 | Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. (Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI) Haematologica 2009 Oct;94(10):1399-406 29 Citations |
| 1 | Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. (Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC) Clin Cancer Res 2009 Jul 15;15(14):4712-21 78 Citations |
| 1 | Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS) J Clin Oncol 2009 Jul 20;27(21):3557-65 230 Citations |
| 3 | Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. (Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ) Eye (Lond) 2010 Apr;24(4):713-6 20 Citations |
| 2 | Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. (George B, Wirostko WJ, Connor TB, Choong NW) J Thorac Oncol 2009 May;4(5):661-2 38 Citations |
| 1 | Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. (Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM) Clin Cancer Res 2009 Mar 01;15(5):1585-92 86 Citations |
| 1 | Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. (Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL) Ann Rheum Dis 2009 Dec;68(12):1863-9 188 Citations |
| 1 | Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. (Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group) Arch Ophthalmol 2009 Jan;127(1):13-21 87 Citations |
| 1 | Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group) Ophthalmology 2009 Jan;116(1):57-65.e5 1280 Citations |
| 1 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7 59 Citations |
| 1 | Short-term response to adalimumab in childhood inflammatory bowel disease. (Noe JD, Pfefferkorn M) Inflamm Bowel Dis 2008 Dec;14(12):1683-7 38 Citations |
| 1 | What's new in clinical pharmacology and therapeutics. (Chawla PS, Kochar MS) WMJ 2008 Apr;107(2):76-83 |
| 1 | Rethinking eligibility creep. (Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB) J Am Acad Dermatol 2008 Jul;59(1):165-7; author reply 167 1 Citation |
| 1 | Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. (Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA) Br J Haematol 2008 Jun;142(2):318-20 7 Citations |
| 1 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R) J Am Acad Dermatol 2008 May;58(5):826-50 1240 Citations |
| 1 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A) J Am Acad Dermatol 2008 May;58(5):851-64 415 Citations |
| 1 | Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. (Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, Shaw BE, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca A) Br J Haematol 2008 Apr;141(2):235-43 43 Citations |
| 1 | Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. (Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM) Oncogene 2008 Jun 26;27(28):3944-56 488 Citations |
| 1 | Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. (Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M) J Dermatolog Treat 2007;18(6):341-50 96 Citations |
| 1 | Bevacizumab in glaucoma: a review. (Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav SS) Can J Ophthalmol 2007 Dec;42(6):812-5 |
| 1 | Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. (Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group) Arch Ophthalmol 2007 Nov;125(11):1460-9 212 Citations |
| 1 | Bevacizumab therapy in patients with recurrent uterine neoplasms. (Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK) Anticancer Res 2007;27(5B):3525-8 40 Citations |
| 1 | Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. (Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K) J Am Acad Dermatol 2008 Jan;58(1):106-15 841 Citations |
| 1 | Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. (Marble DJ, Gordon KB, Nickoloff BJ) J Dermatol Sci 2007 Nov;48(2):87-101 68 Citations |
| 1 | Case reports: efalizumab-associated lymphoproliferative disease. (Bommakanti S, Patil A, Eshoa C, Chitambar CR) J Drugs Dermatol 2007 Jun;6(6):646-8 14 Citations |
| 1 | A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. (Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG) Int J Gynecol Cancer 2008;18(3):400-6 37 Citations |
| 1 | Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Oct;114(10):1868-75 207 Citations |
| 1 | Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. (Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL) Biol Blood Marrow Transplant 2007 Jun;13(6):724-33 11 Citations |
| 1 | Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181 7 Citations |
| 1 | Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. (Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI) Int J Radiat Oncol Biol Phys 2007 Jun 01;68(2):472-8 135 Citations |
| 1 | Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. (Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK) Nat Clin Pract Oncol 2007 May;4(5):316-21 51 Citations |
| 1 | The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. (Shaw BE, Byrne JL, Das-Gupta E, Carter GI, Russell NH) Biol Blood Marrow Transplant 2007 May;13(5):550-9 25 Citations |
| 1 | Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. (Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC) Cancer 2007 Apr 15;109(8):1478-86 202 Citations |
| 1 | Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ) Pediatr Blood Cancer 2008 Mar;50(3):667-70 23 Citations |
| 1 | Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Feb;114(2):246-52 387 Citations |
| 1 | Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). (Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM) Breast J 2007;13(1):72-5 24 Citations |
| 1 | Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. (Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R) Mol Cancer Ther 2006 Dec;5(12):2991-3000 33 Citations |
| 1 | Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group) N Engl J Med 2006 Oct 05;355(14):1432-44 3397 Citations |
| 1 | Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. (Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM) J Am Acad Dermatol 2006 Oct;55(4):598-606 493 Citations |
| 1 | Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 01;107(1):83-9 123 Citations |
| 1 | Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. (Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group) Int J Dermatol 2006 May;45(5):605-14 72 Citations |
| 1 | Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. (Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M) J Cutan Med Surg 2005 Dec;9(6):303-12 30 Citations |
| 1 | Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. (Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS) Gynecol Oncol 2006 Nov;103(2):489-93 100 Citations |
| 1 | The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB) Best Pract Res Clin Gastroenterol 2006 Apr;20(2):365-82 46 Citations |
| 1 | Reversible posterior leukoencephalopathy syndrome and bevacizumab. (Ozcan C, Wong SJ, Hari P) N Engl J Med 2006 Mar 02;354(9):980-2; discussion 980-2 |
| 1 | Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA) J Clin Oncol 2006 Mar 01;24(7):1145-51 199 Citations |
| 1 | Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. (Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group) J Am Acad Dermatol 2006 Apr;54(4 Suppl 1):S164-70 39 Citations |
| 1 | The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. (Gordon KB, Ruderman EM) J Am Acad Dermatol 2006 Mar;54(3 Suppl 2):S85-91 36 Citations |
| 1 | Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. (du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS) Clin Cancer Res 2006 Feb 01;12(3 Pt 1):904-16 131 Citations |
| 1 | Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. (Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB) Clin Ther 2005 Sep;27(9):1317-28 57 Citations |
| 1 | The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. (Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ) Br J Dermatol 2005 Nov;153(5):945-53 60 Citations |
| 1 | Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. (Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group) Br J Haematol 2005 Jun;129(5):631-43 105 Citations |
| 1 | Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. (Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group) J Am Acad Dermatol 2005 Mar;52(3 Pt 1):425-33 225 Citations |
| 1 | Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. (Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W) Arch Dermatol 2005 Jan;141(1):31-8 215 Citations |
| 1 | Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. (Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL, EFALIZUMAB STUDY GROUP) J Drugs Dermatol 2004;3(6):614-24 80 Citations |
| 1 | Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. (Patel T, Gordon KB) Dermatol Ther 2004;17(5):427-31 68 Citations |
| 1 | Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. (Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M) Blood 2004 Aug 01;104(3):655-8 122 Citations |
| 1 | Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. (Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH) Blood 2004 Mar 01;103(5):1969-71 46 Citations |
| 1 | A new era in rheumatoid arthritis treatment. (Costello JC, Halverson PB) WMJ 2003;102(7):29-33 15 Citations |
| 1 | Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. (Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group) JAMA 2003 Dec 17;290(23):3073-80 391 Citations |
| 1 | The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. (Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI, Clinical Trials Committee of the British Society of Blood and Marrow Transplantation) Br J Haematol 2003 Dec;123(5):886-95 24 Citations |
| 1 | Phase II study of alemtuzumab in chronic lymphoproliferative disorders. (Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ) Cancer 2003 Aug 15;98(4):773-8 126 Citations |
| 1 | Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. (Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ) J Gastrointest Surg 2003 Jan;7(1):37-43; discussion 43 65 Citations |
| 1 | Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. (Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R) Clin Cancer Res 2000 May;6(5):1936-48 433 Citations |
| 1 | Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. (Huang SM, Bock JM, Harari PM) Cancer Res 1999 Apr 15;59(8):1935-40 719 Citations |
| 2 | Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. (Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H) Blood 1998 Dec 15;92(12):4581-90 175 Citations |
